Propanc Biopharma accelerates Phase 1b first-in-human PRP trial in advanced solid tumors
Reuters2026/08/06 12:36- Propanc Biopharma on Aug. 6, 2026 flagged new preclinical, early translational PRP data in pancreatic cancer models, not yet presented at a scientific meeting.
- Studies showed strong tumor control, fewer metastases, longer survival, favorable tolerability signals, supporting a differentiated mechanism aimed at resistance.
- Timeline accelerated for a Phase 1b first-in-human trial in advanced solid tumors, with pancreatic cancer a priority; an Australian trial application is planned soon.
- PRP, an intravenous pancreatic proenzyme combination, already holds FDA Orphan Drug Designation for pancreatic cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UBS lowers Ciena target price to $394
EUR/USD Price Forecast: Holds key 100-day SMA at start of the US CPI week
Malaysia Govt Spending Plan Could Help 99 Speed Mart Retail -- Market Talk
Paying the price for supporting the yen? Japan's foreign reserves fell by $87.8 billions in August, possibly due to selling US Treasuries for funding.
Japanese authorities may have used part of their foreign exchange reserves, including foreign securities such as U.S. Treasury bonds, over the past month to fund record-sized foreign exchange intervention operations.
Crypto prices
More
